Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Brenipatide in Uncontrolled Moderate to Severe Asthma
jRCT2071250095Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial of brenipatide in asthma (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment. Started Feb 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2071250095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250095.